New C. Diff Treatment Reduces Infections

New C. Diff Treatment Reduces Infections

New C. Diff Treatment Reduces Infections

New C. Diff Treatment Reduces Infections

A new C. diff (Clostridium difficile) treatment reduces recurrent infections by nearly forty percent ( 40%) according to a recent study.

C. diff(Clostridium difficile) is a bacterium that attacks the bowl, it most commonly causes diarrhea in hospital, nursing facility and subacute patients. The use of standard antibiotic treatment often leads to a recurrence, and hospital readmission which can be fatal.

Researches have found that by adding a drug called Bezliotoxumab to the usual antibiotic protocol they can reduce repeat infection by nearly thirty seven percent (37%). Beziotoxumab is a form of human monoclonal antibody that neutralizes the toxin produced by the C. diff bacteria that can damage the intestinal walls.

According to Professor Mark Wilcox of the University of Leads one in four patients who have received antibiotic treatment for C. diff will have a recurrence of the infection. Professor Wilcox published his findings in the New England Journal of Medicine.

Repeat infections are more difficult to treat, are more severe in nature and can often lead to re-hospitalization. Reduced recurrences would mean a reduction in the use of antibiotics, fewer hospital readmission and reduced costs.

For nursing and subacute facilities this would reduce hospitalizations, reduce empty beds and at the same time reduce the facility costs for isolation and infection control. Currently readmission’s for hospitals are being tracked and financial penalties are being accessed. Nursing and subacute facilities will shortly be in the same position.

The doctors conducted a double blind, randomized, placebo-controlled trial involving 2,655 adults across 300 hospitals in 30 countries world wide.

All of the participating patients had primary or recurrent C. diff infections and were receiving standard-of-care antibiotics, metronidazole, vancomycin or fidaxomicin.

These results will have a significant effect on patient care in hospitals, nursing and subacute facilities. The reduction of antibiotic use, better patient outcomes and the reduction of hospital readmissions is a common goal.

If you enjoyed this article, please like and share it.

Leave a reply